Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare Conference
Tevogen Bio (Nasdaq: TVGN) announced it will host a panel discussion titled 'Pioneering the Economics of Health: Balancing Access and Outcomes' during the 43rd Annual J.P. Morgan Healthcare Conference. The event, scheduled for January 13, 2025, will be held at the Marines' Memorial Club & Hotel in San Francisco.
The panel will feature distinguished healthcare leaders discussing critical aspects of the healthcare ecosystem, including:
- U.S. leadership challenges in healthcare innovation
- Impact of cost-containment measures and the Inflation Reduction Act
- Implications of new administration's healthcare approach on global markets
Panelists include executives from Simon-Kucher, Department of Veterans Affairs, Rubix Health, Tufts Center, and Tevogen Bio leadership. The discussion will run from 3:15 PM to 4:00 PM PST, followed by a reception until 6:00 PM.
Tevogen Bio (Nasdaq: TVGN) ha annunciato che ospiterà una tavola rotonda intitolata 'Pionieri nell'Economia della Salute: Bilanciare Accesso e Risultati' durante la 43ª Conferenza Annuale sulla Salute J.P. Morgan. L'evento, programmato per il 13 gennaio 2025, si terrà al Marines' Memorial Club & Hotel di San Francisco.
Il pannello prevede la partecipazione di eminenti leader nel settore sanitario che discuteranno aspetti critici dell'ecosistema sanitario, inclusi:
- Le sfide della leadership statunitense nell'innovazione sanitaria
- L'impatto delle misure di contenimento dei costi e dell'Inflation Reduction Act
- Le implicazioni dell'approccio sanitario della nuova amministrazione sui mercati globali
I relatori includono dirigenti di Simon-Kucher, Dipartimento degli Affari dei Veterani, Rubix Health, Tufts Center e il leadership di Tevogen Bio. La discussione si terrà dalle 15:15 alle 16:00 PST, seguita da una reception fino alle 18:00.
Tevogen Bio (Nasdaq: TVGN) anunció que será el anfitrión de un panel titulado 'Pioneros en la Economía de la Salud: Equilibrando Acceso y Resultados' durante la 43ª Conferencia Anual sobre Salud de J.P. Morgan. El evento, programado para el 13 de enero de 2025, se llevará a cabo en el Marines' Memorial Club & Hotel en San Francisco.
El panel contará con destacados líderes del sector de la salud que discutirán aspectos críticos del ecosistema de atención médica, incluyendo:
- Desafíos de liderazgo en EE. UU. en innovación sanitaria
- Impacto de las medidas de contención de costos y de la Ley de Reducción de la Inflación
- Implicaciones del enfoque sanitario de la nueva administración en los mercados globales
Los panelistas incluirán ejecutivos de Simon-Kucher, del Departamento de Asuntos de Veteranos, Rubix Health, Tufts Center y la dirección de Tevogen Bio. La discusión se llevará a cabo de 3:15 PM a 4:00 PM PST, seguida de una recepción hasta las 6:00 PM.
Tevogen Bio (Nasdaq: TVGN)는 '건강의 경제학을 선도하다: 접근성과 결과의 균형'라는 제목의 패널 토론을 43번째 연례 J.P. Morgan 헬스케어 컨퍼런스에서 개최한다고 발표했습니다. 이 행사는 2025년 1월 13일에 샌프란시스코의 Marines' Memorial Club & Hotel에서 열릴 예정입니다.
패널은 의료 생태계의 중요한 측면에 대해 논의하는 저명한 의료 리더들로 구성되어 있으며, 논의할 내용은 다음과 같습니다:
- 미국 내 의료 혁신에서의 리더십 도전 과제
- 비용 절감 조치 및 인플레이션 감축 법안의 영향
- 새로운 정부의 의료 접근 방식이 글로벌 시장에 미치는 영향
패널리스트에는 Simon-Kucher, 재향 군인부, Rubix Health, Tufts Center 및 Tevogen Bio의 리더십에서 온 경영진들이 포함됩니다. 논의는 오후 3시 15분부터 4시까지 진행되며, 이후 오후 6시까지 리셉션이 이어집니다.
Tevogen Bio (Nasdaq: TVGN) a annoncé qu'il organisera une table ronde intitulée 'Pionniers de l'économie de la santé : Équilibrer l'accès et les résultats' lors de la 43e Conférence annuelle sur la santé de J.P. Morgan. L'événement, prévu pour le 13 janvier 2025, se déroulera au Marines' Memorial Club & Hotel à San Francisco.
Le panel comprendra des leaders respectés dans le domaine de la santé discutant des aspects critiques de l'écosystème de soins de santé, y compris:
- Les défis du leadership américain en matière d'innovation dans le secteur de la santé
- L'impact des mesures de contrôle des coûts et de la loi sur la réduction de l'inflation
- Les implications de l'approche de la nouvelle administration en matière de santé sur les marchés mondiaux
Les intervenants incluront des dirigeants de Simon-Kucher, du Département des affaires des anciens combattants, de Rubix Health, du Tufts Center et de la direction de Tevogen Bio. La discussion se déroulera de 15h15 à 16h00 PST, suivie d'une réception jusqu'à 18h00.
Tevogen Bio (Nasdaq: TVGN) hat angekündigt, dass es während der 43. jährlichen J.P. Morgan Gesundheitskonferenz ein Podiumsgespräch mit dem Titel 'Pioniere der Gesundheitsökonomie: Zugang und Ergebnisse in Einklang bringen' veranstalten wird. Die Veranstaltung, die für den 13. Januar 2025 geplant ist, findet im Marines' Memorial Club & Hotel in San Francisco statt.
Das Podium wird aus angesehenen Führungskräften im Gesundheitswesen bestehen, die entscheidende Aspekte des Gesundheitsökosystems diskutieren, darunter:
- Herausforderungen der Führung in den USA bei der Gesundheitsinnovation
- Auswirkungen von Kostenkontrollen und dem Inflation Reduction Act
- Folgen des Gesundheitsansatzes der neuen Regierung auf die globalen Märkte
Zu den Podiumsteilnehmern gehören Führungskräfte von Simon-Kucher, dem Ministerium für Veteranenangelegenheiten, Rubix Health, dem Tufts Center und der Führung von Tevogen Bio. Die Diskussion findet von 15:15 bis 16:00 Uhr PST statt, gefolgt von einem Empfang bis 18:00 Uhr.
- None.
- None.
WARREN, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today that it will host a compelling panel discussion, “Pioneering the Economics of Health: Balancing Access and Outcomes,” during the 43rd Annual J.P. Morgan Healthcare Conference.
This panel will bring together global thought leaders to examine the critical interdependencies of the healthcare ecosystem, a dynamic interplay between patient accessibility, medical innovation, reimbursement mechanism and health policy often overlooked when only considering a singular silo of it. The discussion will focus on:
- The challenges and opportunities presented by U.S. leadership in healthcare innovation, particularly in balancing rising costs and value delivery.
- The impact of cost-containment measures, including the Inflation Reduction Act, on drug development and patient access.
- The implications of the new administration’s approach to U.S. healthcare for global markets and business model of medical innovation industry.
Panelists consist of Senior Partner at Simon-Kucher; Former Acting Under Secretary for Health, Department of Veterans Affairs and Former Commissioner, New Jersey Department of Health; Principal, Rubix Health, and Senior Fellow, Tufts Center for Evaluation of Value and Risk in Health and Venture Mentor, Johns Hopkins Tech Ventures, Former CMS Chief Clinical Officer and Director of The Office of Clinical Standards; Managing Director for Risk Advisory Services, Veritas; CEO of Tevogen Bio; CIO and Head of AI at Tevogen Bio.
Event Details
Date:
Monday, January 13, 2025
Location:
Marines’ Memorial Club & Hotel 609 Sutter St, San Francisco, CA 94102, United States
Time (PST):
3:15 PM – 4:00 PM – Pioneering the Economics of Health: Balancing Access and Outcomes
4:00 PM – 6:00 PM – Reception and Cocktails
For inquiries regarding additional event details, please contact communications@tevogen.com.
About Tevogen Bio
Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.
Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
FAQ
When and where is Tevogen Bio's healthcare panel at the JP Morgan Conference 2025?
What topics will be discussed at Tevogen Bio's (TVGN) healthcare economics panel?
Who are the key participants in Tevogen Bio's 2025 JP Morgan Conference panel?
What is the duration of Tevogen Bio's (TVGN) healthcare panel and networking event?
How can investors get more information about Tevogen Bio's JP Morgan Conference panel?
